OptimizeRx (OPRX) Projected to Post Earnings on Thursday

Key Points

• OptimizeRx is expected to announce its Q2 2025 earnings, projecting a profit of $0.03 per share and revenue of $22.27 million, after the market closes on August 7th.
• Despite a previous earnings report showing a profit of $0.08 per share, the company has a negative net margin of 16.33% and is projected to post $0 EPS for both the current and next fiscal years.
• Brokerages have recently reaffirmed or upgraded their ratings on OptimizeRx, with a consensus rating of "Moderate Buy" and an average target price set at $10.81.

OptimizeRx (NASDAQ:OPRX - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect OptimizeRx to post earnings of $0.03 per share and revenue of $22.27 million for the quarter. OptimizeRx has set its FY 2025 guidance at EPS.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 0.29% and a negative net margin of 16.33%. The company had revenue of $21.93 million for the quarter, compared to analysts' expectations of $18.69 million. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptimizeRx Price Performance

Shares of NASDAQ OPRX traded down $0.12 during mid-day trading on Friday, reaching $12.50. The company had a trading volume of 231,661 shares, compared to its average volume of 172,546. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.82 and a current ratio of 2.82. OptimizeRx has a one year low of $3.78 and a one year high of $15.71. The firm has a market cap of $231.25 million, a price-to-earnings ratio of -14.88, a PEG ratio of 4.21 and a beta of 1.33. The business's 50-day simple moving average is $13.36 and its 200 day simple moving average is $9.53.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Roth Capital restated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Stifel Nicolaus raised their price objective on OptimizeRx from $12.50 to $16.00 and gave the company a "buy" rating in a research note on Monday, June 9th. JMP Securities raised their price objective on OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a research note on Tuesday, May 13th. Wall Street Zen raised OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $10.81.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.